The Growing preference for wireless connectivity among healthcare providers, Increasing incidence of cancer worldwide, increasing use of cancer biomarkers in drug discovery development and increasing RD on cancer biomarkers are among the other factors. Emerging economies such as India and Japan are providing lucrative opportunities for the players operating in the Cancer Biomarkers Market.
According to the market research report the global cancer biomarkers market size is projected to reach USD 28.2 billion by 2026 from USD 12.4 billion in 2021, at a CAGR of 17.7%.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202
Browse in-depth TOC on “Cancer Biomarkers Market”
229 – Tables
50 – Figures
287 – Pages
The
protein biomarkers segment accounted for the largest share of the
cancer biomarkers market, by biomarker type segment, in 2020
Based
on biomarkers type, the market is segmented into protein biomarkers,
genetic biomarkers and other cancer biomarkers. The protein biomarkers
segment accounted for the largest share of the cancer biomarker market,
mainly due to rising technological advancements In the development of
cancer biomarkers and increasing RD on cancer biomarkers.
The omics technology accounted for the largest share of the cancer biomarkers market, by profiling technology segment, in 2020
Based
on profiling technology, the market has been segmented into omics
technologies, imaging technologies, immunoassay, bioinformatics, and
cytogenetics. In 2020, the omics technology segment accounted for the
largest share of the cancer biomarker market, mainly due to the
increasing use of cancer biomarkers in drug discovery development and
increasing RD on cancer biomarkers.
Lung cancer segment to register the highest growth rate during the forecast period
The
cancer biomarker market is segmented into breast cancer, lung cancer,
colorectal cancer, prostate cancer, melanoma, leukemia, thyroid cancer,
bladder cancer, non-hodgkins lymphoma, kidney cancer and other cancer
types based on cancer type. In 2020, the breast cancer segment accounted
for the largest share of the cancer biomarkers market. The large share
of this segment can mainly be attributed to the increasing incidence of
cancer worldwide and increasing use of cancer biomarkers in drug
discovery development.
The diagnostics segment accounted for the largest share of the cancer biomarkers market, by application segment, in 2020
Based
on application, the cancer biomarker market has been segmented into
diagnostics, research development, prognostics, risk assessment, and
other applications. In 2020, the diagnostics segment accounted for the
largest share of the cancer biomarker market, mainly due to the
increasing incidence of cancer worldwide and increasing use of cancer
biomarkers in drug discovery development.
North America is the largest regional market for cancer biomarkers market
The
global cancer biomarker market is segmented into five major regions –
North America, Europe, the Asia Pacific, Latin America, and the Middle
East Africa. North America accounted for the largest regional market for
market in 2020. The large share of North America in this market can be
attributed to the rising technological advancements In the development
of cancer biomarkers, increasing incidence of cancer worldwide, and
increasing use of cancer biomarkers in drug discovery development.
Request For Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=202
The major players operating in this Cancer Biomarkers Market
are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific,
Inc. (US), QIAGEN N.V. (Netherlands), ; Illumina, Inc. (US), Bio-Rad
Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US),
Becton, Dickinson and Company (US), Merck Millipore (US), Agilent
Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation
(Japan), Hologic, Inc. (US), Quest Diagnostics (US), Centogene N.V.
(Germany), PerkinElmer, Inc.; (US), Siemens Healthineers (Germany),
Exact Sciences (US), RD Systems, Inc. (US), BioVision, Inc. (US), Olink
(Sweden), Asuragen, Inc. (US), Meso Scale Diagnostics, LLC (US),
Invivoscribe, Inc. (US), Seegene Technologies, Inc. (South Korea).
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/oncology-biomarkers.asp
Content Source: https://www.marketsandmarkets.com/PressReleases/oncology-biomarkers-market.asp
